Статті в журналах з теми "Pseudomonas aeruginosa"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Pseudomonas aeruginosa.

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Pseudomonas aeruginosa".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

FARRAG, SEHAM A., and ELMER H. MARTH. "Behavior of Listeria monocytogenes when Incubated Together with Pseudomonas Species in Tryptose Broth at 7 and 13°C." Journal of Food Protection 52, no. 8 (August 1, 1989): 536–39. http://dx.doi.org/10.4315/0362-028x-52.8.536.

Повний текст джерела
Анотація:
Tryptose broth (TB) was inoculated with Listeria monocytogenes (strain Scott A or California), Pseudomonas aeruginosa, Pseudomonas flourescens, or a combination of L. monocytogenes plus Pseudomonas species, and incubated at 7 or 13°C for 8 weeks. McBride Listeria Agar was used to determine numbers of L. monocytogenes and Pseudomonas Isolation Agar to enumerate Pseudomonas species at 0, 7, 14, 28, 42, or 56 d. At 13°C, presence of P. fluorescens had a slight negative effect on growth of L. monocytogenes strain Scott A, and was somewhat detrimental to its survival during the extended incubation. Growth of L. monocytogenes strain California was retarded by presence of P. fluorescens although the maximum population achieved by the pathogen was greater in the presence rather than absence of the pseudomonad; the pseudomonad did have a negative effect on survival of the pathogen. At the same temperature, P. aeruginosa had a negative effect on survival of L. monocytogenes strain California, but had essentially no effect on the other strain of the pathogen. Neither strain of L. monocytogenes affected growth of P. fluorescens nor P. aeruginosa. At 13°C the pH of TB generally decreased when L. monocytogenes grew by itself but increased when either pseudomonad grew by itself or together with the pathogen. At 7°C, growth of both pseudomonads was minimal. Presence of non-growing cells of P. fluorescens retarded somewhat growth of both L. monocytogenes strains early during the incubation. P. aeruginosa had no detectable effect on either strain of L. monocytogenes. The pH of TB decreased when L. monocytogenes grew by itself or together with either pseudomonad, and remained unchanged in TB inoculated with either pseudomonad.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Young, Heather, Bryan Knepper, Whitney Hernandez, Asaf Shor, Merribeth Bruntz, Chrystal Berg, and Connie S. Price. "Pseudomonas aeruginosa." Journal of the American Podiatric Medical Association 105, no. 2 (March 1, 2015): 125–29. http://dx.doi.org/10.7547/0003-0538-105.2.125.

Повний текст джерела
Анотація:
Background Pseudomonas aeruginosa has traditionally been considered a common pathogen in diabetic foot infection (DFI), yet the 2012 Infectious Diseases Society of America guideline for DFI states that “empiric therapy directed at P aeruginosa is usually unnecessary.” The objective of this study was to evaluate the frequency of P aeruginosa isolated from bone or tissue cultures from patients with DFI. Methods This study is a cross-sectional survey of diabetic patients presenting with a foot infection to an urban county hospital between July 1, 2012, and December 31, 2013. All of the patients had at least one debridement procedure during which tissue or bone cultures from operative or bedside debridements were obtained. The χ2 test and the t test of means were used to determine relationships between variables and the frequency of P aeruginosa in culture. Results The median number of bacteria isolated from DFI was two. Streptococcus spp and Staphylococcus aureus were the most commonly isolated organisms; P aeruginosa was isolated in only five of 112 patients (4.5%). The presence of P aeruginosa was not associated with the patient's age, glycosylated hemoglobin level, tobacco abuse, the presence of osteomyelitis, a prescription for antibiotic drugs in the preceding 3 months, or the type of operative procedure. Conclusions Pseudomonas aeruginosa was an infrequent isolate from DFI in this urban, underserved diabetic population. The presence of P aeruginosa was not associated with any measured risk factors. By introducing a clinical practice guideline, we hope to discourage frontline providers from using routine antipseudomonal antibiotic drugs for DFI.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Weinberg, M. "Pseudomonas aeruginosa." Kazan medical journal 20, no. 5 (August 11, 2021): 551. http://dx.doi.org/10.17816/kazmj76617.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Pennington, James E. "Pseudomonas aeruginosa." Infectious Disease Clinics of North America 4, no. 2 (June 1990): 259–70. http://dx.doi.org/10.1016/s0891-5520(20)30340-8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Hauser, Alan R. "Pseudomonas aeruginosa." American Journal of Respiratory and Critical Care Medicine 178, no. 5 (September 2008): 438–39. http://dx.doi.org/10.1164/rccm.200805-789ed.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Wright, Gordon L. T. "Pseudomonas aeruginosa." Medical Journal of Australia 158, no. 3 (February 1993): 214. http://dx.doi.org/10.5694/j.1326-5377.1993.tb121719.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Chen, Xi, Benjamin S. Bleier, Daniel R. Lefebvre, and Nahyoung Grace Lee. "Pseudomonas Aeruginosa." Ophthalmic Plastic and Reconstructive Surgery 32, no. 5 (2016): 374–77. http://dx.doi.org/10.1097/iop.0000000000000558.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

SHEFF, BARBARA. "Pseudomonas aeruginosa." Nursing 30, no. 5 (May 2000): 79. http://dx.doi.org/10.1097/00152193-200030050-00047.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Cornaglia, G. "Pseudomonas aeruginosa." International Journal of Infectious Diseases 14 (March 2010): e24. http://dx.doi.org/10.1016/j.ijid.2010.02.1541.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Besedin, O. M., S. O. Kosulnikov, L. M. Storubel, S. I. Karpenko, S. O. Tarnopolsky, K. V. Kravchenko, A. S. Kudryavtsev, K. O. Sinitsa, G. M. Pundik, and L. I. Karpenko. "Infections caused by Pseudomonas aeruginosa isolates in patients of Surgical Infections Department." Modern medical technologies 41 part 1, no. 2 (April 6, 2019): 56–60. http://dx.doi.org/10.34287/mmt.2(41).2019.11.

Повний текст джерела
Анотація:
The role of Pseudomonas aeruginosa isolates among the pathogens of surgical infection in purulent-septic surgery department for 2018 is determined. Investigated the antibiotic resistance of Pseudomonas aeruginosa hospital strains and the most effective antibiotics were investigated. Poly resistant in wound material were almost half of the cultures of Pseudomonas aeruginosa (19 strains, 45,2%). Carbapenem resistant Pseudomonas aeruginosa was found to be 47,1%. Of the aminoglycoside group antibiotics, Tobramycin (82,1%) showed the best sensitivity, Amikacin was sensitive in half of the microorganisms tested (55,0%). The sensitivity of cephalosporins ranged from 23,1% (Cefoperazone) to 40,5% (Ceftazidime). Even the use of the Sulbactam protective molecule did not improve the situation: 37,5% (Cefoperazone/ Sulbactam). For fluoroquinolones (Ciprofloxacin) sensitive third part of bacteria only. Piperacillin with Tazobactam, Fosfomycin, and Colistin E showed a high anti-pseudomonad efficacy. The use of anti-diarrhea bacteriophage was ineffective. Keywords: hospital strains, antibiotic resistance, Pseudomonas aeruginosa.
Стилі APA, Harvard, Vancouver, ISO та ін.
11

Miranda Ayala, Marcela Alexandra, and Elsa Noralma Lucas Parrales. "Prevalencia de Pseudomonas Aeruginosa productora de Carbapenemasa en pacientes de cuidados intensivos en hospitales de Latinoamérica." Revista Científica Arbitrada Multidisciplinaria PENTACIENCIAS 5, no. 3 (March 9, 2023): 343–57. http://dx.doi.org/10.59169/pentaciencias.v5i3.546.

Повний текст джерела
Анотація:
Pseudomonas aeruginosa es un patógeno nosocomial causante de múltiples infecciones y actualmente presenta bastante resistencia a diferentes antibióticos carbapenémicos. Objetivo: Establecer la prevalencia de Pseudomonas aeruginosa productora de Carbapenemasa en pacientes de Cuidados Intensivos en hospitales de Latinoamérica. Metodología: El diseño de la investigación fue cualitativo, revisión sistemática, utilizando bases de datos científicas como Cochrane, PubMed, Medigraphic, Redalyc, Scielo y Google académico y revistas científicas como Elsevier desde el año 2017-2022 en idioma inglés y español, para la búsqueda de información se hizo uso de palabras claves y los operadores booleanos como AND, OR y NOT: (Pseudomona aeruginosa) AND (prevalencia Latinoamérica); (Pseudomona aeruginosa) undefined (mecanismo de resistencia) (Pseudomonas aeruginosa), (Pseudomonas aeruginosa) AND (tipo de infecciones). Los artículos incluidos cumplieron criterios de inclusión. Resultados: La prevalencia fue 7,76% en Paraguay, México 7,9% y Colombia 38.8 %. El mecanismo de resistencia más frecuente en Perú, Colombia y Chile fue Carbapenemasa tipo MBL y KPC y en relación del tipo de infección, las más frecuentes fueron bacteriemia y neumonía en México, Colombia y Brasil. Conclusiones: Pseudomonas aeruginosa es una de las bacterias más frecuentemente aisladas en pacientes de unidades de cuidados intensivos en diferentes países de Latinoamérica, presentan multirresistencia a los antibióticos carbapenémicos, causados por diferentes mecanismos de resistencia como carbapenemasas tipo MBL y KPC y los tipos de infección más comunes son bacteriemia y neumonía todo esto ocasiona un mayor tiempo de hospitalización de los pacientes por lo tanto alto costo en el tratamiento.
Стилі APA, Harvard, Vancouver, ISO та ін.
12

Davane, Milind. "Pseudomonas aeruginosa from hospital environment." Journal of Microbiology and Infectious Diseases 4, no. 1 (March 1, 2014): 42–43. http://dx.doi.org/10.5799/ahinjs.02.2014.01.0124.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
13

Balko, O. I., O. B. Balko, and L. V. Avdeeva. "Thermoactivation of Pseudomonas aeruginosa Pyocins." Mikrobiolohichnyi Zhurnal 81, no. 5 (September 30, 2019): 85–97. http://dx.doi.org/10.15407/microbiolj81.05.085.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
14

Fujita, Jiro. "3. Pseudomonas Aeruginosa." Nihon Naika Gakkai Zasshi 97, no. 11 (2008): 2678–86. http://dx.doi.org/10.2169/naika.97.2678.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
15

Moore, Nicholas M., and Maribeth L. Flaws. "Introduction: Pseudomonas aeruginosa." American Society for Clinical Laboratory Science 24, no. 1 (January 2011): 41–42. http://dx.doi.org/10.29074/ascls.24.1.41.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
16

Thi, Minh Tam Tran, David Wibowo, and Bernd H. A. Rehm. "Pseudomonas aeruginosa Biofilms." International Journal of Molecular Sciences 21, no. 22 (November 17, 2020): 8671. http://dx.doi.org/10.3390/ijms21228671.

Повний текст джерела
Анотація:
Pseudomonas aeruginosa is an opportunistic human pathogen causing devastating acute and chronic infections in individuals with compromised immune systems. Its highly notorious persistence in clinical settings is attributed to its ability to form antibiotic-resistant biofilms. Biofilm is an architecture built mostly by autogenic extracellular polymeric substances which function as a scaffold to encase the bacteria together on surfaces, and to protect them from environmental stresses, impedes phagocytosis and thereby conferring the capacity for colonization and long-term persistence. Here we review the current knowledge on P. aeruginosa biofilms, its development stages, and molecular mechanisms of invasion and persistence conferred by biofilms. Explosive cell lysis within bacterial biofilm to produce essential communal materials, and interspecies biofilms of P. aeruginosa and commensal Streptococcus which impedes P. aeruginosa virulence and possibly improves disease conditions will also be discussed. Recent research on diagnostics of P. aeruginosa infections will be investigated. Finally, therapeutic strategies for the treatment of P. aeruginosa biofilms along with their advantages and limitations will be compiled.
Стилі APA, Harvard, Vancouver, ISO та ін.
17

Stratton, Charles W. "Pseudomonas aeruginosa Revisited." Infection Control and Hospital Epidemiology 11, no. 2 (February 1990): 101–4. http://dx.doi.org/10.2307/30144269.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
18

Garau, Javier, and Lucia Gomez. "Pseudomonas aeruginosa pneumonia." Current Opinion in Infectious Diseases 16, no. 2 (April 2003): 135–43. http://dx.doi.org/10.1097/00001432-200304000-00010.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
19

Chen, Sharon C. A., Richard H. Lawrence, Karen Byth, and Tania C. Sorrell. "Pseudomonas aeruginosa bacteraemia." Medical Journal of Australia 159, no. 9 (November 1993): 592–97. http://dx.doi.org/10.5694/j.1326-5377.1993.tb138046.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
20

Stratton, Charles W. "Pseudomonas aeruginosa Revisited." Infection Control and Hospital Epidemiology 11, no. 2 (February 1990): 101–4. http://dx.doi.org/10.1086/646129.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
21

Lin, Ming-Feng, and Yung-Liang Chen. "Pseudomonas aeruginosa Bacteremia." Infectious Diseases in Clinical Practice 14, no. 3 (May 2006): 150–53. http://dx.doi.org/10.1097/01.idc.0000202257.34917.a2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
22

Kipnis, Eric, and Karine Faure. "Pseudomonas aeruginosa bacteremia." Critical Care Medicine 40, no. 4 (April 2012): 1354–55. http://dx.doi.org/10.1097/ccm.0b013e31823c8b55.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
23

Pennington, J. E. "Pseudomonas aeruginosa immunotherapy." European Journal of Clinical Microbiology & Infectious Diseases 9, no. 6 (June 1990): 377–80. http://dx.doi.org/10.1007/bf01979465.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
24

Sheppard, M. "Pseudomonas aeruginosa endocarditis." Journal of Hospital Infection 19, no. 4 (December 1991): 283. http://dx.doi.org/10.1016/0195-6701(91)90246-5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
25

Buchanan, E. B., and S. D. Kominos. "Pseudomonas aeruginosa mastitis." Clinical Microbiology Newsletter 12, no. 8 (April 1990): 63–64. http://dx.doi.org/10.1016/0196-4399(90)90011-y.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
26

Daróczy, Judit. "Erosio interdigitalis caused by Pseudomonas aeruginosa." Bőrgyógyászati és Venerológiai Szemle 95, no. 5 (November 5, 2019): 232–35. http://dx.doi.org/10.7188/bvsz.2019.95.5.6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
27

Norat, Carlos Eduardo Tavares, Luiz Gustavo Pragana, Lizeth Yuliana Acevedo Jaramillo, Rafael de Almeida Travassos, and Ulrich Vasconcelos. "Hydrocarbonoclastic activity in bacterial biofilms: A systematic study emphasizing pseudomonads." Conjecturas 22, no. 12 (September 5, 2022): 548–62. http://dx.doi.org/10.53660/conj-1568-2d01.

Повний текст джерела
Анотація:
Pseudomonas aeruginosa is a ubiquitous fluorescent, rod-shaped pseudomonad, with a high metabolic capacity, and potential for application in processes to remove recalcitrant compounds such as petroleum hydrocarbons (PHC) from the environment. The bacterium persists in sites with highly selective pressures such as those contaminated by PHC. One of the bacterium's strategies is to colonize biofilms which enhance its protection from toxic compounds and favor oil uptake. It is the most prevalent microbe at sites impacted by PHC owing to the use of aliphatic hydrocarbons to form biofilms and other metabolites crucial for the uptake and degradation of crude oil. P. aeruginosa could be useful in biofilm-mediated bioremediation; however, it has been poorly explored in the last ten years. This systematic study addresses recent research on the application of P. aeruginosa/pseudomonads biofilms in bioremediation The studies come from Asia and Africa and emphasized the formation of biofilm by P. aeruginosa and other pseudomonads as crucial elements in the detoxification process of the environment.
Стилі APA, Harvard, Vancouver, ISO та ін.
28

Danela, Siti, Lalu Sri Gede, and Pancawati Ariami. "KACANG KEDELAI SEBAGAI MEDIA ALTERNATIF PERTUMBUHAN BAKTERI PSEUDOMONAS AERUGINOSA." Jurnal Analis Medika Biosains (JAMBS) 6, no. 1 (July 18, 2019): 73. http://dx.doi.org/10.32807/jambs.v6i1.127.

Повний текст джерела
Анотація:
Kacang kedelai (Glycine max L. Merr) merupakan sumber protein, dan lemak, serta sebagai sumber vitamin A, E, K, dan beberapa jenis vitamin B dan mineral K, Fe, Zn, dan P. Pada penelitian ini masalah yang akan di jawab apakah penggunaan kacang kedelai (Glycine max L.Merr) dapat digunakan sebagai media alternatif untuk pertumbuhan bakteri Pseudomonas aeruginosa. Tujuan penelitian ini untuk mengetahui penggunaan biji kacang kedelai (Glycine max L. Merr) sebagai media alternatif untuk pertumbuhan bakteri Pseudomonas aeruginosa. Metode penelitian yang digunakan bersifat Quasi experiment dengan rancangan penelitian Posstest Only Control Group Design. Data hasil dianalisis secara deskriptif. Dari hasil penelitian diperoleh bahwa tepung kacang kedelai dapat menumbuhkan bakteri Pseudomonoas aeruginosa padakonsentrasi 2%, 4%, 6%, dan 8%. Hasil penelitian menunjukan bahwa tepung kacang kedelai dapat dimanfaatkan sebagai salah satu sumber protein untuk pertumbuhan bakteri Pseudomonas aeruginosa.
Стилі APA, Harvard, Vancouver, ISO та ін.
29

Balko, O. B. "Low Molecular Weight Pseudomonas aeruginosa Bacteriocins." Mikrobiolohichnyi Zhurnal 81, no. 6 (November 30, 2019): 97–109. http://dx.doi.org/10.15407/microbiolj81.06.097.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
30

O. Rifai, Ahmad, Abeer M. Abd El-Aziz, and Hany I. Kenawy. "Possible antivirulent activity of some agents against clinical isolates of Pseudomonas aeruginosa." EJMM-Volume 30-Issue 2 30, no. 2 (April 1, 2021): 1–8. http://dx.doi.org/10.51429/ejmm30201.

Повний текст джерела
Анотація:
Background: Pseudomonas aeruginosa has developed different mechanisms of resistance against antibiotics and became one of the most life-threatening pathogens. Fighting against its virulence Factors are an alternative therapeutic target. Objective: This study was directed towards the investigation of anti-quorum sensing activity and inhibitory action on virulence factors of different agents including antibacterial agents to which Pseudomonas aeruginosa isolates are resistant and non-antibacterial agents. Methodology: Anti-quorum sensing activity of ceftriaxone, ceftazidime (CAZ), cefepime (FEP), vancomycin (VA), paracetamol (PA), and pheniramine maleate (PHE) investigated as well as their ability to reduce other virulence factors including protease, hemolysin, and pyocyanin production. Results: This study showed that 3rd and 4th generations cephalosporins could be used as anti-quorum sensing agents effectively in the treatment of Pseudomonas aeruginosa infections, however, vancomycin, paracetamol, and pheniramine maleate had no effect on inhibiting the studied virulence factors. Conclusion: From our study we conclude that although cephalosporins at the used concentrations did not show anti-pseudomonal activity they were effective as anti virulent agents that could be utilized in therapeutically in controlling Pseudomonas aeruginosa infections.
Стилі APA, Harvard, Vancouver, ISO та ін.
31

Martusevich, Andrey K., Ivan V. Bocharin, and Marina N. Ivashchenko. "The effect of antiseptics on the crystallogenic properties of Pseudomonas aeruginosa." Veterinariya, Zootekhniya i Biotekhnologiya 1, no. 11 (2021): 47–52. http://dx.doi.org/10.36871/vet.zoo.bio.202111006.

Повний текст джерела
Анотація:
The aim of the work was to clarify the crystallogenic properties of pseudomonads under the action of an antiseptic. The material for the study was 8 strains of Ps. aeruginosa. In accordance with the purpose and objectives of the study, the work was carried out in 3 stages: assessment of the biological properties of the isolated pseudomonas strains; determination of sensitivity to disinfectants by the squares method; assessment of the crystallogenic (initiating) the activity of pseudomonads in an individual and joint form with a disinfectant. The tested antiseptic was "Desam" in the form of a standard 1% solution. Most of the analyzed strains turned out to be sensitive to the applied working concentration of the tested disinfectant and are active initiators of the crystallogenesis of sodium chloride solution. The revealed significant differences in the tesigraphic test conducted with pseudomonas strains sensitive and resistant to the studied disinfectant create prerequisites for the development of a new express method for determining the sensitivity of microorganisms to disinfectants.
Стилі APA, Harvard, Vancouver, ISO та ін.
32

Mubassu, Polly, Abednego Musyoki, Erick Odoyo, Collins Kigen, and Lillian Musila. "Environmental reservoirs of multidrug-resistant pseudomonads in a geographical location in Kenya with high community-acquired infections." F1000Research 13 (May 13, 2024): 474. http://dx.doi.org/10.12688/f1000research.147914.1.

Повний текст джерела
Анотація:
Background Pseudomonads are gram negative bacteria and readily form biofilms in the environment, allowing long-term colonization and persistence in sinks, water systems. They pose a risk of life-threatening opportunistic infections in immune-compromised individuals. MDR strains, make treatment increasingly difficult. Environmentally persistent MDR strains are typically problematic within healthcare facilities, however, data on MDR pseudomonad reservoirs in settings with community-acquired infections to inform preventive interventions, in resource-constrained settings is scarce. Here, we determined reservoirs and antibiotic susceptibility of Pseudomonas species in water sources in Kisumu County, Kenya with reported high levels of community acquired pseudomonad infections. Methods We adopted a cross-sectional design, randomly collecting 297 samples from tap heads, sinks, tanks, vendor and household storage containers in six selected sub-locations and one hospital (KCRH). Standard microbiological procedures were used for identification and AST of the isolates. Results We isolated Pseudomonads from 14.1% of the samples collected, predominantly from the community 10.4%. Seven different pseudomonads were identified, with Pseudomonas aeruginosa predominating 6.7% overall, in the community samples 5.7%, and among isolates from water tanks 21.4%. Pseudomonad isolates were 62% non-susceptible to piperacillin, 57% to tigecycline, 24% meropenem, 21% cefepime, 19% levofloxacin and 14% colistin. Carbapenem resistance was mainly detected in P. aeruginosa 80% (8/10) from Milimani sub-location 75% (6/8). 45% of the isolates recovered were MDR, mainly community-associated carbapenem-resistant P. aeruginosa (CRPA) 42%, strains susceptible to colistin. The MDR pseudomonads exhibited high multiple antibiotic resistance indices, ranging from 0.43 to 1. Conclusion This study reveals a higher prevalence of MDR pseudomonads, including CRPA strains in community water sources. These potential conduits of drug resistance present a critical public health threat, especially among immunocompromised. Regular cleaning of water storage facilities, water treatment and implementation of antimicrobial stewardship programs, are required to prevent a rise in AMR and eliminate the environmental reservoirs that put the vulnerable populations at risk.
Стилі APA, Harvard, Vancouver, ISO та ін.
33

Ikhsan, Fajri, Ahmad Shulhany, and Syarif Abdullah. "Metallothionein Protein Modeling from Pseudomonas aeruginosa PAO1 as A Metal Biosorber Candidate." Jurnal Biodjati 8, no. 2 (November 28, 2023): 248–61. http://dx.doi.org/10.15575/biodjati.v8i2.29170.

Повний текст джерела
Анотація:
Metallothionein is a protein that is well known to play a role in metal metabolism in bacterial cells. Metallothionein is a multifunctional protein that has the potential to be used as a metal adsorbing agent. Pseudomonas aeruginosa is a ubiquitous gram-negative and rapid-growth bacterium. In addition, the complete genome of Pseudomonas aeruginosa has been largely known. Pseudomonas aeruginosa PAO1 is a strain of Pseudomonas aeruginosa that the complete genome of this strain is easily accessible in NCBI. These features make Pseudomonas aeruginosa PAO1 become a common model in bacterial studies. This research aimed to find and model the putative metallothionein of Pseudomonas aeruginosa PAO1. This research was carried out by bioinformatic and protein homology methods. Based on the results, the putative metallothionein of Pseudomonas aeruginosa PAO1 was found in the bacterial genome at base sequence of 2355918 to 2356157. The putative metallothionein-encoding gene of Pseudomonas aeruginosa PAO1 has a size of 240 bp. The translation result of the gene showed that the putative metallothionein of Pseudomonas aeruginosa PAO1 has 79 amino acids. The modeling result showed the 3D structure of the putative metallothionein of Pseudomonas aeruginosa PAO1 is similar to the metallothionein 3D structure of Pseudomonas fluorescens Q2-87. The 3D structure of the putative metallothionein of Pseudomonas aeruginosa PAO1 was dominated by turn and coil, but contained 1 α-helix structure and 2 β-sheet structures. Based on protein analysis, it was found that the putative metallothionein of Pseudomonas aeruginosa PAO1 has 1 metal-binding cluster with 10 amino acids and the most important amino acid residue is Cysteine . Even though, there was 1 Histidine amino acid residue on the metal-binding cluster.
Стилі APA, Harvard, Vancouver, ISO та ін.
34

Gailienė, Greta, Alvydas Pavilonis, and Violeta Kareivienė. "The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups." Medicina 43, no. 1 (January 17, 2007): 36. http://dx.doi.org/10.3390/medicina43010005.

Повний текст джерела
Анотація:
Pseudomonas aeruginosa is one of the most common nonfermenting aerobic gramnegative microorganisms identified in clinical specimens of hospitalized patients. The emergence of multidrug-resistant (MDR) Pseudomonas aeruginosa strains is a growing concern in hospitalacquired infections. Typing of strains is important for identifying the sources of infection as well as prevention of cross-infections and monitoring of the efficacy of antimicrobial therapy. The aim of this study was to evaluate the antimicrobial resistance and prevalence of Pseudomonas aeruginosa serogroups isolated at Kaunas University of Medicine Hospital, Lithuania. Material and methods. Minimum inhibitory concentrations of piperacillin, cefoperazone, ceftazidime, cefotaxime, cefepime, imipenem, meropenem, gentamicin, amikacin, tobramycin, and ciprofloxacin for 609 Pseudomonas aeruginosa strains isolated from various clinical specimens between November 2001 and November 2002 were determined by the microdilution method in Mueller–Hinton agar using interpretative guidelines of National Committee for Clinical Laboratory Standards. Serogroups of Pseudomonas aeruginosa strains were identified using serums of Seiken Co. Ltd (Tokyo, Japan), containing antibodies against antigens of Pseudomonas aeruginosa O-group. Results. Pseudomonas aeruginosa strains were the most sensitive to ceftazidime (78.9%), imipenem (73.6%), meropenem (70.9%) and the most resistant to gentamicin (54.1%) and ciprofloxacin (52.5%). Multidrug-resistant strains made up 9.85% of all Pseudomonas aeruginosa strains investigated. Multidrug-resistant Pseudomonas aeruginosa strains were 1.5–3.5 times more resistant to antibiotics compared to non-multidrug-resistant strains, except to amikacin: multidrug-resistant strains were more sensitive (81.7%) than non-multidrug-resistant Pseudomonas aeruginosa strains (61.0%). Pseudomonas aeruginosa serogroups O:E and O:B were the most common serogroups (34.7% and 29.0%, respectively) followed by serogroups O:I (11.4%) and O:A (10.1%). Pseudomonas aeruginosa serogroup O:E strains were the most prevalent among multidrug-resistant strains (48.3%). Conclusions. The results of our study show that serogroup O:E was the most prevalent serogroup of Pseudomonas aeruginosa in our hospital, and its resistance to antibiotics was the highest.
Стилі APA, Harvard, Vancouver, ISO та ін.
35

Ullah, Munzer, Hayat Ullah, Khaliq Noor, Maliha Sarfraz, Misbah Ullah Khan, Uzma Bibi, Ghulam Nabi, Maheen Kanwal, Kainat Ramzan, and Ahmed M. Metwaly. "Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Hospital Environment." Volume 4 Issue 1, Volume 4 Issue 1 (September 11, 2021): 40–50. http://dx.doi.org/10.34091/ajls.4.1.5.

Повний текст джерела
Анотація:
Pseudomonas aeruginosa is a leading cause of disease and death particularly in cystic fibrosis patients and also considered resistance to chemotherapeutic agents. Therefore, it is very difficult to remove the Pseudomonas aeruginosa from the hospital environment by using simple techniques. In the contemporary study, biofilm mediated mechanism of various antimicrobial responses were analyzed. For this purpose, different Pseudomonas aeruginosa clinical isolates were collected from Pakistan medical institute Islamabad (PIMS) hospital and were investigated for pellicle formation. Pseudomonas aeruginosa isolates were studied for different groups of antibiotics including imipenem, meropenem, ceftazidime, amikacin, tobramycin, gentamicin, piperacillin, cefoperazone, and cefotaxime. The goal was to check antimicrobial susceptibility of pseudomonas aeruginosa which shows resistant to tobramycin, imipenem, meropenem, amikacin, gentamicin, cefotaxime, piperacillin, ceftazidime, cefoperazone. Additionally, in this study, Pseudomonas aeruginosa strains were also investigated for pellicle formation. In conclusion, this research work wills highlights the useful mechanism of antibiotics resistance to Pseudomonas aeruginosa infections in clinical practice. Keywords: Antibiotics, Pseudomonas aeruginosa, antibiotics, Biofilm, Peliclle.
Стилі APA, Harvard, Vancouver, ISO та ін.
36

Chakraborty, Tamalika, Tushar Gupta, Nayana Verma, Zarin Parwez, Kaustav Deb, and Tamoghana Chakraborty. "PREVALENCE OF ANTIBIOTIC RESISTANCE IN PSEUDOMONAS AERUGINOSA." International Journal of Advanced Research 12, no. 01 (January 31, 2024): 1249–60. http://dx.doi.org/10.21474/ijar01/18243.

Повний текст джерела
Анотація:
One of the main bacteria responsible for hospital-acquired illnesses is Pseudomonas aeruginosa. Through chromosomal changes or the horizontal acquisition of resistant determinants, antibiotic resistance can be easily developed it. High-risk clones, like ST175, are spreading together with the rising frequency of extensively-drug-resistant (XDR) or multi-drug-resistant (MDR) P. aeruginosa isolates. MDR/XDR infections should be taken seriously since they can make it difficult to choose the best empirical and conclusive antimicrobial therapies. New avenues for the treatment of MDR/XDR P. aeruginosa infections have been opened by the introduction of powerful new antibiotics. Pseudomonas aeruginosa strains are known to withstand the majority of antibiotics by utilizing their high levels of intrinsic and acquired resistance mechanisms. Furthermore, recalcitrance and infection recurrence are caused by P. aeruginosas adaptive antibiotic resistance, a recently identified process that combines biofilm-mediated resistance and the development of multidrug-tolerant persister cells. There is a growing need for and interest in the research and development of alternative therapeutic approaches that offer fresh approaches to combat P. aeruginosa infections. Much recent research has documented various novel therapeutic methods that have proven pronouncedly effective in treating drug-resistant P. aeruginosa strains, but largely at the preclinical stages. This review focuses on the Prevalence of antibiotic resistance in Pseudomonas aeruginosaand also provides an overview of the characteristics of pseudomonas bacteria, various infections caused by them, the mechanism of antibiotic resistance, their clinical implications, Challenges in treatment, strategies for management and control, and future perspectives and research directions.
Стилі APA, Harvard, Vancouver, ISO та ін.
37

Pokharel, Khilasa, Bishwa Raj Dawadi, Chandra Prakash Bhatt, and Satish Gupte. "Prevalence of Pseudomonas aeruginosa and its Antibiotic Sensitivity Pattern." Journal of Nepal Health Research Council 17, no. 01 (April 28, 2019): 109–13. http://dx.doi.org/10.33314/jnhrc.v17i01.1877.

Повний текст джерела
Анотація:
Background: Pseudomonas aeruginosa is an opportunistic pathogen which causes most of the chronic infection in humans. This study was undertaken to determine the prevalence rate of Pseudomonas aeruginosa that is isolated from various clinical specimens along with its antibiotic susceptibility pattern.Methods: This descriptive cross sectional study was conducted in Kathmandu Medical College and Teaching Hospital (KMCTH) from February to May 2018. Pseudomonas aeruginosa isolated from various clinical specimens were processed in clinical laboratory, Department of Microbiology, KMCTH. Isolation, identification and sensitivity of Pseudomonas aeruginosa to antibiotics were measured.Results: A total of 7527 samples were been processed of which 46 isolates of Pseudomonas aeruginosa were obtained. Pseudomonas aeruginosa was isolated mainly from Pus, Wound swab, Sputum and Tracheal aspirate. Here 63.04% Pseudomonas aeruginosa isolates were resistant to Ceftazidime, 65.21% to Cefixime, 56.52% to Ceftriaxone and Cefotaxime followed by 56.52% to Piperacillin. Furthermore, the current study reveals antibiotics like Imipenem, Meropenem, Piperacillin/Tazobactam, Ciprofloxacin, Gentamicin, Amikacin and Tobramycin were found to be good choice for the treatment of infection caused by this organism.Conclusions: Continuous monitoring of antibiotic susceptibility pattern of Pseudomonas aeruginosa is essential and rational treatment regimens prescription by the clinicians is required to limit the spread of antimicrobial resistance.Keywords: Antibiotic resistance; clinical isolates; Pseudomonas aeruginosa.
Стилі APA, Harvard, Vancouver, ISO та ін.
38

Kylat, Ranjit I. "Pseudomonas aeruginosa necrotizing bronchopneumonia." Autopsy Case Reports 11 (2021): e2021271. http://dx.doi.org/10.4322/acr.2021.271.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
39

Mehmood, Yasir, Muhammad Imran Ashraf, Shazana Rana, Humayun Riaz, Syed Atif Raza, and Zia mohy-ud-din Khan. "ANTI-PSEUDOMONAS AERUGINOSA DRUG." Professional Medical Journal 25, no. 10 (October 10, 2018): 1574–80. http://dx.doi.org/10.29309/tpmj/18.4509.

Повний текст джерела
Анотація:
Objectives: In this research we assess in-vitro susceptibility of Pseudomonasaeruginosa (P. aeruginosa) using the ethanolic extract of medicinal plant Tabebuia impetiginosa(dried inner bark). To evaluate the synergistic effect of ethanolic extract of Tabebuia impetiginosacombine with ciprofloxacin In-vitro anti-Pseudomonas aeruginosa activities of the extracts andciprofloxacin were confirmed, and synergism was verified for this combine extracts. StudyDesign: Experimental study. Period: October 2016 to February 2017. Place of Experiment:Rashid Latif Medical College, Lahore. Method: Diffusion method tests are mostly qualitativemethods that are used to identify the antimicrobial activity, resistance and synergistic effect. Thefresh plants inner bark was grinded and soaked in 95% ethanol for extraction. The antibacterialsensitivity of this compound against P. aeruginosa was assessed using the diffusion method.About 1000mg of grinded menstruum was added in 800ml of petroleum ether in a conicalflask and adjust in rotary shaker at 100 rpm for 12 hours and then the final extract was filteredwith 0.45mμ filter membrane and centrifuged at 2000rpm for 15 minutes. The final extract wasredissolved in ciprofloxacin solution (10 for bioassay analysis. Results: We concludedthat the fresh ethanolic extract of Tabebuia impetiginosa with ciprofloxacin has high antibacterialpotency against P. aeruginosa which is prominent then a single. However this was not pureextract and if it is refined then it might gives significant antibacterial activity at low concentration.There is still need to test Tabebuia impetiginosa extract for antibacterial activity and to checksynergistic effect with other drugs in-vivo against Pseudomonas aeruginosa. Extract presentedthe highest synergism rate with antimicrobial drug. Conclusion: In-vitro study showed Tabebuiaimpetiginosa fresh inner bark extract with ciprofloxacin dilution have significant antibacterialactivity against Pseudomonas aeruginosa with P.value <0.001. Isolates were susceptible tothis combine solution with mean zone diameter of 16.15 ± 0.95 mm and no regrowth wasnoticed. In the present research the synergistic effect of ciprofloxacin antibiotic with Tabebuiaimpetiginosa ethanolic extract were observe against Pseudomonas aeruginosa bacteria.
Стилі APA, Harvard, Vancouver, ISO та ін.
40

Fernández-Barat, Laia, Victoria Alcaraz-Serrano, Rosanel Amaro, and Antoni Torres. "Pseudomonas aeruginosa in Bronchiectasis." Seminars in Respiratory and Critical Care Medicine 42, no. 04 (July 14, 2021): 587–94. http://dx.doi.org/10.1055/s-0041-1730921.

Повний текст джерела
Анотація:
Abstract Pseudomonas aeruginosa (PA) in patients with bronchiectasis (BE) is associated with a poor outcome and quality of life, and its presence is considered a marker of disease severity. This opportunistic pathogen is known for its ability to produce biofilms on biotic or abiotic surfaces and to survive environmental stress exerted by antimicrobials, inflammation, and nutrient or oxygen depletion. The presence of PA biofilms has been linked to chronic respiratory infection in cystic fibrosis but not in BE. There is considerable inconsistency in the reported infection/eradication rates of PA and chronic PA. In addition, inadequate antimicrobial treatment may potentiate the progression from intermittent to chronic infection and also the emergence of antibiotic resistance. A better comprehension of the pathophysiology of PA infections and its implications for BE is urgently needed. This can drive improvements in diagnostic accuracy, can move us toward a new consensus definition of chronic infection, can better define the follow-up of patients at risk of PA, and can achieve more successful eradication rates. In addition, the new technological advances regarding molecular diagnostics, -omics, and biomarkers require us to reconsider our traditional concepts.
Стилі APA, Harvard, Vancouver, ISO та ін.
41

Mikkelsen, Ole Steen. "SEROTYPING OF PSEUDOMONAS AERUGINOSA." Acta Pathologica Microbiologica Scandinavica 73, no. 3 (August 17, 2009): 373–90. http://dx.doi.org/10.1111/j.1699-0463.1968.tb04606.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
42

Mikkelsen, Ole Steen. "SEROTYPING OF PSEUDOMONAS AERUGINOSA." Acta Pathologica Microbiologica Scandinavica Section B Microbiology and Immunology 78B, no. 2 (August 15, 2009): 163–75. http://dx.doi.org/10.1111/j.1699-0463.1970.tb04283.x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
43

Dowling, Ruth B., and Robert Wilson. "Pseudomonas Aeruginosa Respiratory Infections." Clinical Pulmonary Medicine 6, no. 5 (September 1999): 278–86. http://dx.doi.org/10.1097/00045413-199909000-00002.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
44

Eraksoy, Haluk. "Carbapenem-Resistant Pseudomonas aeruginosa." Klimik Dergisi/Klimik Journal 27, no. 2 (June 10, 2015): 37. http://dx.doi.org/10.5152/kd.2014.11.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
45

Garnotel, Éric. "Avant-Propos – Pseudomonas aeruginosa." Revue Francophone des Laboratoires 2011, no. 435 (September 2011): 33–34. http://dx.doi.org/10.1016/s1773-035x(11)71099-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
46

M., J. M. "Bactériophages contre Pseudomonas aeruginosa." Revue Francophone des Laboratoires 2016, no. 485 (September 2016): 14. http://dx.doi.org/10.1016/s1773-035x(16)30260-x.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
47

Ara Martín, Mariano, Estrella Simal Gil, María Luisa Zubiri Ara, and Pedro Zaballos Diego. "Foliculitis por Pseudomonas aeruginosa." Actas Dermo-Sifiliográficas 94, no. 1-2 (October 2003): 107–9. http://dx.doi.org/10.1016/s0001-7310(03)79235-7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
48

Mérens, A., P. Jault, L. Bargues, and J. D. Cavallo. "Infections à Pseudomonas aeruginosa." EMC - Maladies infectieuses 10, no. 1 (February 2013): 1–18. http://dx.doi.org/10.1016/s1166-8598(12)56974-7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
49

Romero, Fátima Tous, Virginia Velasco Tamariz, and Sara Burillo Martínez. "Foliculitis por Pseudomonas aeruginosa." FMC - Formación Médica Continuada en Atención Primaria 24, no. 3 (March 2017): 170. http://dx.doi.org/10.1016/j.fmc.2016.03.005.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
50

Morand, A., and J. J. Morand. "Pseudomonas aeruginosa en dermatologie." Annales de Dermatologie et de Vénéréologie 144, no. 11 (November 2017): 666–75. http://dx.doi.org/10.1016/j.annder.2017.06.015.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії